New models towards assessing anti-cancer therapeutics.
New models towards assessing anti-cancer therapeutics.
复制标题
DOI：
10.14670/hh-27.157
复制
发表时间：
2012-02
影响因子：
2
通讯作者：
Isabel Romero-Camarero;Marcos Barajas-Diego;A. Castellanos-Martín;Á. García-Martín;G. Varela;M. Abad;M. Ludeña;J. Pérez-Losada;I. Sánchez-García
中科院分区：
文献类型：
--
作者：
Isabel Romero-Camarero;Marcos Barajas-Diego;A. Castellanos-Martín;Á. García-Martín;G. Varela;M. Abad;M. Ludeña;J. Pérez-Losada;I. Sánchez-García
癌症是世界各地密集研究的主题，但有关疾病如何工作的许多问题仍然没有答案。癌症是如何开始的，肿瘤是如何生长的？事实上，目前正在进行临床试验的抗癌药物比15年前多10倍。然而，预计许多新的抗癌药物仅在一小部分患者中显示出临床获益。癌症干细胞模型不仅可以解释一些癌症是如何工作的，还可以解释为什么患者会复发，这为在进入临床试验之前深入了解药物有效或更常见的无效的原因提供了一个很好的机会。
Cancer is the subject of intense research around the world, but many questions about how the disease works remain unanswered. How exactly does cancer start and how do tumours grow? In fact, at present there are ten times more anticancer drugs being tested in clinical trials than there were 15 years ago. However, many of the new anticancer agents are predicted to show clinical benefit in only small subpopulations of patients. The cancer stem cell model could explain not only how some cancers work but also why patients suffer relapses, providing a good opportunity to gain insight into the reasons why agents work or, more commonly, don't work, before going into a clinical trial.